Greetings from CEO
Dear valuable customers,
I would like to take this opportunity to express my sincere thanks for the support and cooperation from my clients since Genolution’s establishment in 2006.
It has been a long-cherished desire of mankind to live a happy life without the disturbances caused by disease. Owing to the magnificent progress of modern science, the expected life span has increased tremendously in Korea. For example, the average life span has lengthened by 19 years for both men and women, more specifically, from 58.6 to 77.6 in men and 65.6 to 84.4 in women from 1970 to 2011. However, the span of a healthy life is still only 68.79 years for men and 72.84 years for women which means there is a considerable period of suffering from various diseases regardless of gender.
Genolution was established with the ambitious motto of “Free from Disease” in order to produce molecular diagnostics products and is proud of the successful launch of its exclusive reagents as well as the Nextractor, which is regarded as one of the most efficient and economical DNA/RNA extraction instruments. We are contributing to the early diagnostics of disease by providing these products to numerous universities, university hospitals, reference labs and Institutions of Disease Research, etc. Additionally, RNA synthesis and RNAi services for Herbicide and Insecticide have been developed in the company to a considerable extent to contribute to the enhancement of domestic health.
In 2015, we successfully accomplished KONEX listing of our share in Korea Stock Exchange and realized a turnaround by making KRW 16.6MM of operating income and KRW 81.4MM of net profit. Meanwhile, Distribution Agreements with agents in China and Italy in 2016 along with our highly developed technology and R&D investments are expected to trigger sales increases internationally and domestically in the years to come.
As the CEO, I would like to proclaim that Genolution will continue to relentlessly strive to not only serve as a molecular diagnostics company, but also to act as a company-to-be of Global Life Science in order to improve the futures of our clients, shareholders and the health of humanity.
I would like to thank our valued customers and shareholders again and express my gratitude for your continuous support and cooperation.
Thank you.
I would like to take this opportunity to express my sincere thanks for the support and cooperation from my clients since Genolution’s establishment in 2006.
It has been a long-cherished desire of mankind to live a happy life without the disturbances caused by disease. Owing to the magnificent progress of modern science, the expected life span has increased tremendously in Korea. For example, the average life span has lengthened by 19 years for both men and women, more specifically, from 58.6 to 77.6 in men and 65.6 to 84.4 in women from 1970 to 2011. However, the span of a healthy life is still only 68.79 years for men and 72.84 years for women which means there is a considerable period of suffering from various diseases regardless of gender.
Genolution was established with the ambitious motto of “Free from Disease” in order to produce molecular diagnostics products and is proud of the successful launch of its exclusive reagents as well as the Nextractor, which is regarded as one of the most efficient and economical DNA/RNA extraction instruments. We are contributing to the early diagnostics of disease by providing these products to numerous universities, university hospitals, reference labs and Institutions of Disease Research, etc. Additionally, RNA synthesis and RNAi services for Herbicide and Insecticide have been developed in the company to a considerable extent to contribute to the enhancement of domestic health.
In 2015, we successfully accomplished KONEX listing of our share in Korea Stock Exchange and realized a turnaround by making KRW 16.6MM of operating income and KRW 81.4MM of net profit. Meanwhile, Distribution Agreements with agents in China and Italy in 2016 along with our highly developed technology and R&D investments are expected to trigger sales increases internationally and domestically in the years to come.
As the CEO, I would like to proclaim that Genolution will continue to relentlessly strive to not only serve as a molecular diagnostics company, but also to act as a company-to-be of Global Life Science in order to improve the futures of our clients, shareholders and the health of humanity.
I would like to thank our valued customers and shareholders again and express my gratitude for your continuous support and cooperation.
Thank you.
Gi Ok Kim
CEO